Greatest Breakthrough in Medical History Keith Kohl 29

27/08/23, 14:53 Greatest Breakthrough in Medical History
Have you ever found yourself standing at the pharmacy counter, shocked at
the price of a tiny bottle of pills?
Perhaps you've wondered at one point or another, Why does my prescription

medication cost so much?
Or maybe you've waited anxiously for a new treatment only to be told it's
still years away from reaching the market.
If you've had any of these experiences, you're not alone; the cost and time it
takes to develop new drugs these days can be difficult to cope with.
Last year, the median price of new medicines hit an astonishing record:
$257,000 for a single year of treatment.
It’s hard to imagine how it’s come to this, but there's a reason why this is
happening...
In the world of pharmaceuticals, the journey from "bench to bedside" is a

long, winding road.
https://secure2.angelpub.com/o/web/608711?utm_optipub=email-promo&identifier=9149b333f51d07f3bd86bbc4268b9d64&utm_referrer=3 1/29
It's a marathon of research, trials, and regulatory hurdles that can stretch
over a decade and cost billions of dollars for drug developers.
The process is arduous, expensive, and outdated...
And it’s causing innocent people to suffer every day.
Of course, it’s easy to point fingers at pharmaceutical companies for all

this...
But the reality of skyrocketing drug prices is a bit more complicated than
mere corporate greed.
You see, what most people haven’t been told is that the return on
investment (ROI) for new drugs has been plunging to dangerous levels in
recent years...
And because of these rising costs, most pharmaceutical companies are

now fighting for their lives.
In fact, last year, ROI on novel drug development fell to just 1.2% — the
lowest percentage on record.
That’s less than you can get with a savings account.
Now, most people couldn’t care less about the pharma industry’s ROI, but
it’s critical to understand that these economics have put us in a
predicament...
A predicament where the cost of making new drugs has become so high
that pharmaceutical innovation is beginning to buckle under the pressure.
Consider this:
In 2018, 59 new drugs made it to market.
But last year, that number cratered to just 37...
Which means drug development and innovation are suddenly collapsing...
And it’s no surprise when you consider the data.
Just to give a few examples:
90% of drug candidates in clinical trials now fail to reach approval.

The cost of making a single therapeutic now exceeds $2.3 billion on
average.
It now takes 10.5 years for a drug to progress through clinical trials.
For pharmaceutical companies, this all equates to a huge financial risk...
And for many, it’s no longer a risk worth worth taking.
Today, there is not a single industry on Earth that spends more on research
and development than the pharmaceutical industry...
Not the auto industry...
Not aerospace and defense...
Not even tech.
On average, pharmaceutical companies are now spending 25% of their

revenue on R&D. That’s roughly double the proportion they spent in 2000.
And the problem for drugmakers only seems to be accelerating.
In only a five-year period, spending on pharma R&D has increased nearly

50%...
All the while, the ROI on these drug development programs is crashing...
down to just 1.2% again.
You don’t need to have a finance degree to understand why this trend is not
sustainable.
Unless we significantly improve

efficiencies in drug development
ASAP, we risk a massive drought

in pharmaceutical innovation.
Because once that ROI goes negative, the financial incentive to make new
medicine will completely disappear.
And whether we like it or not, profit is what drives innovation in this industry.
As The New York Times puts it in a recent excerpt:
First Big Pharma fled the field, and now startups are going belly
up, threatening to stifle the development of new drugs.
And pharmaceutical giants, despite their mountains of cash, aren’t going to

step in to save us...
Because here’s a truth that the world’s largest pharmaceutical companies

don’t want you to know...
The vast majority of drug development today doesn’t happen under their
watch.
In fact, over 70% of new drugs that reach late-stage clinical trials these
days are created by small drug companies with revenue of less than $500
million.
For years, Big Pharma has been using these smaller and more innovative
companies to offload their risk.
They wait to see which drugs make it through the arduous testing phase
and then they leverage their cash hordes and entrenched distribution
channels to broker a deal.
As you might expect, these deals are absolutely ruthless.
Typically, pharma giants are leaving negotiations with 93% of all revenue a
drug will ever make (despite often having nothing to do with its
development).
This strong-arming tactic has served the multibillion-dollar pharma

companies well for a while...
But coupled with rising R&D costs, it’s now threatening to destroy their
innovation engine completely.
You see, healthcare bankruptcies just exploded 84% year over year...
And it’s the smaller companies — the ones actually innovating — that are
cracking under all the pressure.
Unfortunately, many of these companies aren’t going to make it through the

next decade...
And the fallout for unsuspecting investors could be devastating.
But as is true with just about

any economic crisis, this one
hides an ENORMOUS opportunity
for those who position
themselves accordingly.
You see, the skyrocketing cost of drug development has ignited
unprecedented demand within the pharmaceutical industry for an entirely
new model of innovation...
One that will drastically increase the efficiency of discovering and

developing new medical treatments...
Because without a major leap forward like this, the pharma industry is dead
in the water.
However, as the saying goes, necessity is the mother of invention.

And a technological breakthrough has emerged in the midst of this crisis...
One that will not only save us from a looming drug development drought
but also propel us into a new golden age of medicine.
This is an opportunity that every serious investor needs to start paying

attention to yesterday...
And something everyone will be buzzing about tomorrow.
We’re talking about a groundbreaking method of inventing new medicine

that:
Is up to 10 times faster than conventional drug discovery...

Reduces development costs by up to 80%...
Is sparking what Morgan Stanley estimates to be a "$50 billion
opportunity" for investors.
After months of research, I’m fully convinced that this new model of drug
development is going to upend the entire pharmaceutical industry and will
launch us into a golden age of medicine.
Instead of taking years to reach pharmacy shelves, new medicines will

soon only take months...
And instead of costing several billions of dollars to develop, they will cost
in the millions.
More importantly, though, these drugs will work better than anything that
was previously thought possible.
We’re talking about a new category of medicine that is magnitudes more

effective than modern drugs...
Not to mention virtually absent of harmful side effects.
This groundbreaking class of

new drugs is known as "Algo
Meds."
That’s short for "Algorithmic Medicine."
And I’m going to show you how it all works in a moment...
But as Ohio State University reports, know first that it will create a future of
"better, more potent [drugs]."
And as Harvard University explains, Algo Medicine "holds massive potential

to increase the accessibility of drugs and to treat presently incurable
conditions."
That’s right — diseases once believed to be incurable are going to be wiped

off the face of the Earth by Algo Meds.
It’s only a matter of time.
Conditions like cancer, Alzheimer’s, and heart disease could soon all be
obliterated by Algo Meds.
And, unsurprisingly, investment in this emerging technology has absolutely

skyrocketed in recent years.
A decade ago, Algorithmic Medicine didn’t even exist. Today, there are
already tens of billions of dollars invested in it:
And from the looks of it, we’re only just getting started.
As you would expect, Big Pharma is starting to leap on the opportunity and
is already racing to establish a foothold.
Pfizer, AstraZeneca, and Sanofi have all announced collaborations to begin

developing drugs using Algorithmic Medicine...
Which is one of the reasons you should consider this message extremely
urgent.
You see, these pharma giants are loaded with cash — and they’re
desperate for more efficient drug discovery methods...
Which means they will be doing whatever they can to get their hands on
Algo Meds and the technology behind it.
But here’s the thing...
Big Pharma companies are not leading in the development of this new wave
of drugs — they’re chasing it.
And they’re losing the race to a little-known biotech company spearheading

this medical revolution.
This company, which trades at

around $5 at the time of this
writing, is the definition of
first-mover advantage.
It recently designed the first drug ever to enter human clinical trials using
this new method of drug discovery.
And it already has five new drugs in the pipeline.
Even better, most of these molecules are majority-owned, which means this
company knows what it has and isn’t caving to Big Pharma pressure.
Yet Big Pharma is still clamoring for any access it can get to this company’s
Algo Meds and expertise.
Bristol-Myers Squibb, Bayer, and Sanofi are all already working with this
company directly...
So it’s not too surprising that this $5 stock is already stirring up a lot of
early buzz in Wall Street circles.
BlackRock and Citigroup are both building positions...
As is Bill Gates, who is personally funding the company’s research.
I promise you this is not just marketing hype: This is genuinely one of the
most compelling public investment opportunities I have come across in
my lifetime.
I’ll tell you more about this company in a minute so you can claim a stake
today for a shot at truly life-changing stock returns...
But first, you should probably understand exactly what Algorithmic

Medicine is and why it’s destined to disrupt the $1.42 trillion
pharmaceutical industry.
If you haven’t figured it out

already, we’re talking about AI-
driven drug discovery.
Artificial intelligence has been feeding a ton of hype into the stock market in
recent months.
And you should know out the gate that most of that hype is complete bunk.
Much like what happened during the dot-com boom, companies are coming
out of the woodwork and name-dropping AI to get your attention...
And investors are falling for it hook, line, and sinker.
But the company I’m telling you about today is not riding some AI hype
train.
It began using a process called "machine learning" for pharmaceutical

development years before ChatGPT even hit the scene.
Machine learning is a branch of artificial intelligence that uses data and

algorithms to imitate the way humans learn...
Hence the term "Algorithmic Medicine."
And in 2020, this company created the first ever drug developed by machine
learning to enter human clinical trials — the first Algo Med.
Today, this company has multiple AI-generated molecules in its clinical

pipeline..
And at least one of those Algo Meds is already on the precipice of being
approved by the FDA.
In short...
This company’s "Algo Med" could

become the first AI drug in
history.
If and when it’s approved, this

company's share price will go
absolutely bonkers.
Hi, my name is Keith Kohl.
I’ve been professionally trading biotech stocks for close to a decade.
And if there’s one thing I’ve learned about making money in this space, it’s
that the biggest returns happen hard and fast.
That’s why I’m reaching out to you with this urgent message today...
Because when small drug developers like this company make a major
breakthrough, share prices tend to ignite like wildfire... and by the time you
hear about it on CNBC, it’s always too late.
My job is to identify these kinds of events well ahead of time so you can
profit.
I’ve been doing this for years, locating some of the market’s biggest single-
day stock returns in history...
And sharing those opportunities with people like you.
Take Aquinox Pharmaceuticals, for example...
Aquinox was once a little-known biotech firm with a market cap of just
$15.6 million — tiny for any sector.
But today, the company is notorious amongst traders.
Just a few short years ago, Aquinox reported clinical trial results for its new
bladder pain drug, AQX-1125.
The results were drastically better than the market was expecting, and
investors watched shares explode from less than $2 to over $55 in a single
trading session
Imagine turning that kind of a profit in a single day.
It’s the kind of return that could literally transform your life.
With a modest investment, you could afford a new house and pay for it in
cash.
You would never have to worry about your retirement again...
And you’d have the means to travel the world, as your friends and former
colleagues watch in envy.
Of course, a 3,000% gain like this in a day isn’t commonplace.
Considering all the stocks you can buy on any given day, it’s actually
extremely rare — almost like hitting the lotto.
But massive price swings happen in small biotech stocks like this all the
time.
You just need to know where to look.
You see, for small drugmakers on the verge of major medical

breakthroughs, like the AI drugmaker I’ve been telling you about, critical
events like data releases and FDA decisions mean feast or famine.
And every few weeks, routine events like these create extremely profitable
trading windows for savvy speculators. The average investor just isn’t
aware of it.
Take Amarin Corporation as another example.
This New Jersey-based pharmaceutical company specializes in novel

treatments for cardiovascular disease.
When it announced clinical trial results for its new drug Vascepa... Well, just
look at what happened:
Shares climbed from $2.99 to $12.40 in a single day of trading — a gain of

314%.
That’s more than a 3x gain... IN A DAY!
And the stock kept climbing after that.
Within 30 days, shares climbed to $22.98, giving investors a return of 669%!
Now, I’m not going to sugarcoat it — this is a high-risk way to chase wealth.
However, in my experience, the rewards of investing in groundbreaking

medicine are too immense to ignore, especially when you know how to
stack the odds in your favor with quick, in-and-out trades.
There are many ways to stack the odds in your favor...
But the single most important thing is to chase only the biggest
opportunities...
Because if you’re making a $1,000 investment with the chance to profit

$50,000, a single win will still outweigh dozens of losses.
It’s an investing philosophy known as "asymmetric risk and reward"...
And it’s the most reliable method for finding huge stock returns that I have
ever come across.
You accept that there’s a chance things won’t go your way...
And that when they do, you will make out like a bandit.
And that’s exactly what I expect will happen for investors when this AI
drugmaker gets its first drug approved...
Because this is an absolutely monumental event, and it will send a clear

message to the entire market that:
The golden age of "Algo Meds" is

emerging, and THIS is the
company leading the way.
Remember, this company is not chasing some trend — it’s literally at the
very tip of the spear in practical AI.
In 2020, it was the first company to put a molecule designed by AI into

clinical trials...
And its cancer-crushing Algo Med is already on the verge of FDA approval
(despite the fact that it takes 10 years for a drug to clear these hurdles on
average).
But what does any of this even mean?
How can AI design a therapeutic medication?
Well, I’m not going to bog you down with a boring, hours-long lesson on
coding and biology...
But please consider this image for a moment:
What you see here isn’t a pile of ribbons; it’s a protein structure, visualized
by a computer.
The green "ribbon" is what the protein actually looks like...
And figuring that out isn’t exactly easy.
For the last half-century, scientists have had to use highly complex methods
like X-ray crystallography to get a clear picture of a protein.
This process, known as solving a protein’s structure, can take years to

work... and most of the time, it doesn’t even work at all.
In fact, of the 200 million different proteins known to man, structures like
the one you see above have been solved for only about 170,000 proteins
using conventional methods.
It’s something scientists have been trying to solve for over 50 years — an
extremely difficult mountain that humans have been unable to traverse.
But here’s where things get exciting.
The blue ribbon is what artificial intelligence predicted the same protein
structure would like.
It’s almost a perfect match... and it took just 30 minutes for the AI to
accomplish.
In fact, AI has already mapped out over 300,000 proteins this way. That’s
nearly double what humans have been able to accomplish over the last half-
century.
The importance of this is difficult to overstate.
It’s an absolute game-changer for drug development...
Because it means artificial intelligence is now capable of mapping out

biology at a level of precision and speed that just a few years ago was
completely unimaginable.
It’s like the difference between putting a puzzle together with a blindfold on
versus having detailed instructions on every single piece.
And it’s not just protein structures AI can model; every aspect of
biochemistry can be mapped out and simulated.
In doing so, Algorithmic Medicine is:
Drastically speeding up the drug discovery process

Reducing enormous costs associated with running physical labs
Unlocking a world of possibility for drug developers leveraging this
opportunity
And believe me when I say there is not a single company advancing AI drug
development faster than the $5 company we’ve been talking about.
Today, this company trades for less than $1 billion.
By the end of the decade, it will

be a household name in
medicine, like Pfizer, Merck, or
even
Johnson & Johnson.
Eventually, I expect this $5 stock

will even leave these legacy
drugmakers in the dust...
The same way modern antibiotics replaced penicillin...
And how modern painkillers replaced morphine.
Algo Meds promise to be better than every prescription medicine on the

shelf today.
As MIT engineer Matthew Chun explains:
If current trends continue, it will only be a matter of time before

the drugs we take are no longer designed by people but by
machines. With the promise of lower costs and shorter
development timelines, AI-enabled drug discovery holds massive
potential.
And there is no reason why current trends would not continue.
The low-hanging fruit in drug development is simply gone; conventional

drug development has become too complicated, too time-consuming, and
too expensive.
That’s why this $5 AI drug developer is a game-changer... and my absolute

top stock pick of the decade.
It’s already shown a 70% reduction in drug discovery time...
As well as an 80% increase in cost efficiency...
Not to mention its first cancer treatment is currently flying through clinical
trials.
It’s no wonder big names like Bill Gates, BlackRock, Citigroup, and others
are all quietly scooping up shares.
But just because smart money has started to get involved does not mean
it’s too late.
There is still time to claim your stake alongside them.
However, that window of opportunity is not going to be open for long...
Because shares are likely to climb whenever this company clears a new
hurdle in the regulatory process.
Phase 2 data is just around the corner...
Which means this company is about to make public exactly how well its
new AI cancer drug works...
And if the data is what we expect — or better — this is going to be the first
major price move.
Now, just to be clear: I think there’s going to be a lot of money to be made at

all stages of this process...
But the highest potential gains are going to be secured now, not later.
By the time Phase 2 data is released, this $5 stock could very well be
trading at $20.
By then, most of the opportunity will be gone, or at least a huge chunk of

it...
Which means if you want a piece of Algorithmic Medicine, the time to act is
not next week...
Not tomorrow...
Not even in a few hours, when you might forget.
The time to act is NOW.
That’s why I’m going to share all

the details about this tiny AI
drug developer with you in a
brief and straightforward
investment guide.
It’s called "Algo Meds: Cashing in on AI Drug Development Before It’s Too
Late."
Inside this report, you’ll find the name and ticker symbol of this obscure AI
drugmaker I’ve been telling you about.
You’ll also get all my analysis on this burgeoning firm, including a detailed
company profile, financial and valuation analysis, commentary, and price
targets.
You will also find the dates of all upcoming events that I expect to move the
price of this company’s stock.
To claim this report immediately, you simply need to sign up for a trial run
of my exclusive trading advisory Topline Trader.
Subscribe in the next hour through this offer, and I’ll give you 90 days to
test-drive the advisory and everything we have to offer.
If you aren’t loving it, you don’t pay a dime.
Either way, you get all the information detailed above inside the report.
Of course, you can put me through the wringer if you really want.
You can keep the information for free and bail after three months...
But the truth is I don’t expect you to do that because the ongoing intel
Topline Trader will provide you with is truly invaluable.
As I mentioned earlier, my name is Keith Kohl.
I have been investing in biotech and pharma stocks professionally for many
years...
And I’ve developed a unique trading system for taking advantage of major
price swings in this sector.
I know the biotech industry inside and out...
And I can tell you this strategy is unrivaled by anything I’ve come across in
my decades-long investing career.
Even during the most recent market meltdown, you could’ve made a LOT of
money trading the kinds of unique pharmaceutical events we target.
In fact, we didn’t have a single losing trade in Topline Trader in one of the
worst years in stock market history.
We had 21 closed trades last year — and all 21 were winners.
Just recently, one of our open positions surged 190% in less than two
months.
And we plan to find many more trades like these in the months to come.
How exactly do we locate these opportunities?
Well, we start by scouring through hundreds of conference calls and press

releases of every small-cap biotech stock on the market.
We map out every major upcoming event in their drug pipelines — data
readouts, FDA approvals, the works.
We then put the most critical events on a calendar and mark them as
potential swing-trading opportunities.
Next, we use our private network of over 250 bench scientists and Ph.D.s to
analyze each of those new drug candidates...
And we combine all this with historical data to determine the likelihood that
a drug will make it through regulatory approval.
We call this unique percentage figure the "Chance of Success"...
And as a member of Topline Trader, you can use this information however
you like.
But our core strategy is to make a trade only when a drug has an extremely
high Chance of Success...
And only leading up to key dates when a single press release can send
shares flying.
But here’s the best part...
You don’t need a Ph.D. in chemistry or physics to participate in any of our

strategies.
We’re here to break it all down in simple, easy-to-understand terms.
My goal is to make this as easy — and profitable — as possible for you.
Here’s a short list of some recent biotech winners, just to give you an idea
of how profitable this sector can be:
3,278% on Aquinox Pharmaceuticals

190% on ProQR Therapeutics
212% on Prana Biotechnology
54% on Dova Pharmaceuticals
86% on Aldeyra Therapeutics
87.3% on Viking Therapeutics
113.3% on Editas Medicine
669% on Amarin Corporation
Of course, these are just a few extraordinary examples.
The opportunity I’ve been telling you about today is bigger than anything
else I’ve covered over the course of my career.
As soon as your membership is confirmed, you can expect:
Weekly issues — These are packed with new and exciting research
on the hottest biotechnology companies on Earth. I’ll introduce you
to a breakthrough company in at least one of these issues every
month. You get the name of the company, specific buy instructions,
the works.
Real-time buy and sell alerts — In this fast-moving market,
opportune buy and sell points can come at any time. And I'll make
sure you receive them the moment they arrive for the biggest
potential profits.
Specific entry, exit, and target prices — You'll never have to guess if
a stock is a good buy or not. I'll always give you specific entry points,
sell prices, and realistic targets for our recommendations.
Complete research for every recommendation — You'll always know
exactly why I recommend a stock. You'll get my complete analysis,
what catalysts to expect, and why I believe it’ll be a winner. That way,
you'll be able to invest and profit with confidence.
Unlimited access to our private, members-only website — This is
where you can read all our back issues and reports, gain access to
our biotech events calendar, and review my full history of

recommendations.
Access to our VIP member services line — A subscription to Topline
Trader qualifies you for VIP service. You can contact the VIP team
with any questions at 844-310-4115.
But don’t just take it from me. My readers will tell you better than anyone
what a wild ride my research services can be:
I love love love [my subscription]. I just recently started

investing and could not have chosen a better investment
newsletter. The information provided in my subscription is
easy to follow, full of expert insight, and the
recommendations pay off in a major way. The thing that
sets this letter apart from all the rest is the ability to
locate solid under the radar companies that will shape the
way we live everyday life.
— Christopher J.
The [information] has proven invaluable. Of all the

recommendations I am exposed to, whether by other
newsletters or fellow investors, [these] recommendations
have borne the most fruit...The only limitation is lack of
action! The track record speaks for itself.
— Matt S.
As the authority on tech stocks, [Keith’s team] does the

research and keeps handing members one home run after
another. My [membership] was a bargain that paid for
itself in days.
— Lisa M.
I really enjoy Keith’s commentary and his stock calls have

been pretty much dead on. [Keith’s newsletter] has been
the best money I've ever invested.
— Glyn T.
Nothing makes me happier than hearing my readers’ success stories.
That’s why I make sure to put out only the absolute best investment
opportunities I find.
However, before you claim your report, I want to be upfront about

something...
Topline Trader isn’t going to be suited for everyone. To get the most out of
it, you’ll need to be comfortable taking higher-than-average risks.
You have to focus on high-reward opportunities with the potential to

multiply your money many times over.
Only investors willing to take advantage of these kinds of trades have the
chance to beat the markets many times over.
If you’re this type of investor, I’ll happily welcome you as a new member.
Get Started Today for 60% Off

Now, I'm sure you're wondering by now how much it costs to become a
member of Topline Trader...
So let me be straight.
Providing this level of service isn’t cheap.
The full-time staff, the proprietary data networks, the secure U.S. servers...
The network of 250 biopharmaceutical experts weighing in on every new

drug...
All of that requires a significant investment on our end.
And when you consider that you could easily make six figures on your first
trade alone...
I know that Topline Trader would offer HUGE value even at a list price of
$10,000 a year.
But I’m doing something very special for everyone watching this today.
I’m offering a special limited discount because I don’t want people to miss
out on life-changing profits.
So here’s the deal...
If you join today, you won’t pay anywhere near $10,000.
You won’t even pay 50%, 60%, or 70% of that price.
Even if you did, Topline Trader would still be a shockingly good value.
But I’m not content with just making it a good value...
I want this to be the best decision you’ve made all year.
So if you test-drive Topline Trader today, I’m going to knock 60% off the
usual retail price.
Once you join, you’ll start receiving regular trade recommendations directly
from my desk and our newest special report, "Algo Meds: Cashing in on AI
Drug Development Before It’s Too Late."
I’m also going to throw in our full library of reports, which includes dozens
of company profiles and investment guides, including:
"Nanotechnology, Mega-Profits: Topline’s Top 3 Nanotech Stocks to

Buy Today"
"Titan Gains: How to Earn Massive Profits on Massive Biotech
Stocks"
"The Biotech Investor’s Guide to FDA Fast Lanes"
And as I mentioned, you’re protected by...
Topline Trader’s Ironclad 100%

Satisfaction Guarantee
You’ll have three months to check out Topline Trader and all the profit
opportunities it offers.
If you don't like it, don't keep it. If you decide it's not for you within that
three-month trial period, you'll be covered by our full money-back
satisfaction guarantee.
During that time, you'll have full membership access. You can log into the
private members site, check out all the special reports, and view every
update I've posted.
If you find that Topline Trader isn't what you thought, let me know. I'll refund
every penny you've spent on the subscription — no questions asked.
Any information, reports, and profits you received courtesy of my service

will be yours to keep.
You won't find an opportunity like this anywhere else. With the amount of
information I'll be giving you FREE of charge, taking a trial run of Topline
Trader is a no-brainer.
So if making the investment of a lifetime is something you're ready to do,

lock in your spot today.
The only drawback here is that with the way things are progressing with this
AI drugmaker, there might not be a tomorrow.
So click the "Join Now" button below to get started.
But please hurry...
We’re only opening 45 slots through this offer today. Any more than that
risks diluting profits for our other members.
Unfortunately, this number is nonnegotiable.
We're dealing with one of the tiniest stocks on the market here.
Any big influx of readers can push up share prices and adversely affect
everyone's profit potential.
So I really must limit Topline Trader’s membership.
If you're late to respond to this invitation, your name will go on a waiting list
with potentially thousands of other readers. That's why I recommend
subscribing right now if this is something you're interested in.
It's easy to do.
Simply click the button below that says "Join Now," complete the secure
invitation form, and you'll be in!
It only takes seconds.
Don't put off living the good life any longer than you already have.
Click here to get started.
To your wealth,
Keith Kohl
Investment Director, Topline Trader
Angel Publishing LLC, a general interest newsletter is not liable for the suitability or future investment performance of any securities or strategies discussed.
Please note that we are not a registered investment firm or broker/dealer. Only a registered broker or investment adviser may advise you individually on the
suitability and performance of your portfolio or specific investments.
Readers are advised that the material contained herein should be used solely for informational purposes. As a publisher of a financial newsletter of general
and regular circulation, we cannot tender individual investment advice. We urge you to always conduct your own research and due diligence and obtain
professional advice before making any investment decision.
We will not be liable for any loss or damage caused by a reader's reliance on information obtained on our web sites. Our readers are solely responsible for
their own investment decisions. Historical investment return examples given are hypothetical, and not to be taken as representative of any individual's actual
trading experience. Please click here to see our Details and Disclosures

Greatest Breakthrough in Medical History Keith Kohl 29

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Greatest Breakthrough in Medical History Keith Kohl 29

Uploaded by

Copyright:

Available Formats

27/08/23, 14:53 Greatest Breakthrough in Medical History

Perhaps you've wondered at one point or another, Why does my prescription

In the world of pharmaceuticals, the journey from "bench to bedside" is a

The process is arduous, expensive, and outdated...

And it’s causing innocent people to suffer every day.

Of course, it’s easy to point fingers at pharmaceutical companies for all

And because of these rising costs, most pharmaceutical companies are

That’s less than you can get with a savings account.

In 2018, 59 new drugs made it to market.

But last year, that number cratered to just 37...

Which means drug development and innovation are suddenly collapsing...

And it’s no surprise when you consider the data.

Just to give a few examples:

90% of drug candidates in clinical trials now fail to reach approval.

For pharmaceutical companies, this all equates to a huge financial risk...

And for many, it’s no longer a risk worth worth taking.

Not the auto industry...

Not aerospace and defense...

Not even tech.

On average, pharmaceutical companies are now spending 25% of their

And the problem for drugmakers only seems to be accelerating.

In only a five-year period, spending on pharma R&D has increased nearly

Unless we significantly improve

ASAP, we risk a massive drought

As The New York Times puts it in a recent excerpt:

And pharmaceutical giants, despite their mountains of cash, aren’t going to

Because here’s a truth that the world’s largest pharmaceutical companies

As you might expect, these deals are absolutely ruthless.

This strong-arming tactic has served the multibillion-dollar pharma

Unfortunately, many of these companies aren’t going to make it through the

And the fallout for unsuspecting investors could be devastating.

But as is true with just about

One that will drastically increase the efficiency of discovering and

However, as the saying goes, necessity is the mother of invention.

And a technological breakthrough has emerged in the midst of this crisis...

This is an opportunity that every serious investor needs to start paying

And something everyone will be buzzing about tomorrow.

We’re talking about a groundbreaking method of inventing new medicine

Is up to 10 times faster than conventional drug discovery...

Instead of taking years to reach pharmacy shelves, new medicines will

We’re talking about a new category of medicine that is magnitudes more

Not to mention virtually absent of harmful side effects.

This groundbreaking class of

And I’m going to show you how it all works in a moment...

And as Harvard University explains, Algo Medicine "holds massive potential

That’s right — diseases once believed to be incurable are going to be wiped

It’s only a matter of time.

And, unsurprisingly, investment in this emerging technology has absolutely

Pfizer, AstraZeneca, and Sanofi have all announced collaborations to begin

But here’s the thing...

And they’re losing the race to a little-known biotech company spearheading

This company, which trades at

And it already has five new drugs in the pipeline.

BlackRock and Citigroup are both building positions...

As is Bill Gates, who is personally funding the company’s research.

But first, you should probably understand exactly what Algorithmic

If you haven’t figured it out

And investors are falling for it hook, line, and sinker.

It began using a process called "machine learning" for pharmaceutical

Machine learning is a branch of artificial intelligence that uses data and

Hence the term "Algorithmic Medicine."

Today, this company has multiple AI-generated molecules in its clinical